Bruno Daniele

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al. · Journal of Clinical Oncology · 2019 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +13

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.7K citations

Medicine, Oncology, Pharmacology +13

Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies

Steven A. Curley, Francesco Izzo, Paolo Delrio et al. · Annals of Surgery · 1999 · 1.1K citations · Full text

Medicine, Oncology, Surgery +17

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel, Andrés Cervantes, Ian Chau et al. · Annals of Oncology · 2018 · 1.1K citations · Full text

Medicine, Oncology, Surgery +14